Will an Opioid Manufacturer Stage a Comeback With This New Venture?
Investors in Endo International (NASDAQ: ENDP) have seen the stock decimated by persistent declines in demand for prescription painkillers and nationwide opioid litigation. The company's spending on research and development has been less than its competitors' for years, but results may be on the horizon at last. Will the company's new Biologic License Application to treat cellulite in a billion-dollar market be able to reverse its fortune?
Image Source: Getty Images
On July 6, the U.S. Food and Drug Administration (FDA) will decide whether to expand Endo's Xiaflex label to target cellulite, a localized alteration of the skin affecting up to 85% to 98% of adult women in all ethnicities. Xiaflex is an injectable enzyme that strengthens the connective tissues between the skin, causing it to push out lipids responsible for the condition. If approved by the FDA, the drug will become the first pharmaceutical treatment for cellulite in a market estimated to be worth more than $1 billion.
Source Fool.com
